国药控股20240430

Summary of Conference Call Transcript Industry or Company Involved - The discussion pertains to the industry impacted by pandemic control measures and the recovery of business operations in 2023, specifically referencing a company named 诺德 (Nord). Core Points and Arguments - The reduction in performance is attributed to the gradual lifting of pandemic control measures in 2023, which allowed for a rapid recovery of various business operations [1] - The high comparative base from the previous year has made it challenging to maintain revenue growth, indicating that achieving year-on-year growth in revenue is particularly difficult given the strong performance in the same period last year [1] - The impact of industry regulation and transformation on the market landscape is acknowledged, suggesting that the company is navigating a changing environment [1] - The revenue scale maintaining year-on-year growth despite these challenges is highlighted as a significant achievement [1] Other Important but Possibly Overlooked Content - The context of comparing the current performance to the first quarter of the previous year, which was heavily influenced by pandemic restrictions, is essential for understanding the current results [1]